Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review ; volume:24 ; number:1 ; day:20 ; month:8 ; year:2024 ; pages:1-14 ; date:12.2024
BMC cancer ; 24, Heft 1 (20.8.2024), 1-14, 12.2024
- Creator
-
Ram, Malihe
Afrash, Mohammad Reza
Moulaei, Khadijeh
Parvin, Mohammad
Esmaeeli, Erfan
Karbasi, Zahra
Heydari, Soroush
Sabahi, Azam
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12764-y
- URN
-
urn:nbn:de:101:1-2411110949208.673813283754
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:25:06+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ram, Malihe
- Afrash, Mohammad Reza
- Moulaei, Khadijeh
- Parvin, Mohammad
- Esmaeeli, Erfan
- Karbasi, Zahra
- Heydari, Soroush
- Sabahi, Azam
- SpringerLink (Online service)
Other Objects (12)
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants